NO20061513L - Kondensert ringforbindelse og anvendelse derav - Google Patents

Kondensert ringforbindelse og anvendelse derav

Info

Publication number
NO20061513L
NO20061513L NO20061513A NO20061513A NO20061513L NO 20061513 L NO20061513 L NO 20061513L NO 20061513 A NO20061513 A NO 20061513A NO 20061513 A NO20061513 A NO 20061513A NO 20061513 L NO20061513 L NO 20061513L
Authority
NO
Norway
Prior art keywords
sinusitis
chronic
compound
condensed ring
ring compound
Prior art date
Application number
NO20061513A
Other languages
English (en)
Norwegian (no)
Inventor
Tadashi Tatsumi
Yoshisuke Nakayama
Jun Takeuchi
Shinya Takahashi
Satoshi Itadani
Manabu Fujita
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20061513L publication Critical patent/NO20061513L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C205/60—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms in ortho-position to the carboxyl group, e.g. nitro-salicylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061513A 2003-09-01 2006-04-03 Kondensert ringforbindelse og anvendelse derav NO20061513L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003309232 2003-09-01
JP2003369547 2003-10-29
PCT/JP2004/012563 WO2005021518A1 (fr) 2003-09-01 2004-08-31 Composé cyclique condensé et son utilisation

Publications (1)

Publication Number Publication Date
NO20061513L true NO20061513L (no) 2006-06-01

Family

ID=34277677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061513A NO20061513L (no) 2003-09-01 2006-04-03 Kondensert ringforbindelse og anvendelse derav

Country Status (14)

Country Link
US (2) US7763610B2 (fr)
EP (2) EP1661892B1 (fr)
JP (1) JP4720502B2 (fr)
KR (1) KR101135911B1 (fr)
AU (1) AU2004268865B8 (fr)
BR (1) BRPI0413968A (fr)
CA (1) CA2537355C (fr)
ES (1) ES2425746T3 (fr)
IL (1) IL173898A (fr)
MX (1) MXPA06002152A (fr)
NO (1) NO20061513L (fr)
NZ (1) NZ545666A (fr)
RU (1) RU2371436C2 (fr)
WO (1) WO2005021518A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560513A (en) 2005-02-25 2010-07-30 Ono Pharmaceutical Co Indole compound and use thereof
TWI406664B (zh) * 2006-03-30 2013-09-01 Univ Kyoto 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑
TWI469965B (zh) * 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
MY162757A (en) * 2010-06-21 2017-07-14 Ono Pharmaceutical Co New Crystalline Forms of 4,4’-[4-Fluoro-7-({4-[4-(3-Fluoro-2-Methylphenyl) Butoxy] Phenyl}Ethynyl)-2-Methyl-1H-Indole-1, 3-Diyl] Dibutanoic Acid
WO2013066838A1 (fr) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Composés et procédés
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
WO2016057693A1 (fr) 2014-10-10 2016-04-14 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour administration par inhalation d'oligonucléotide conjugué

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (fr) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
US4618361A (en) * 1983-12-12 1986-10-21 Ciba-Geigy Corporation Acylamides and compositions for the protection of cultivated plants against the phytotoxic action of herbicides
CA1261835A (fr) * 1984-08-20 1989-09-26 Masaaki Toda Benz(thio) amides fusionnes
CA2019335C (fr) 1989-06-27 2000-08-01 Mitoshi Konno Acides phenylakan(en)oiques
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5468898A (en) * 1990-09-10 1995-11-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity
US5696117A (en) * 1995-11-07 1997-12-09 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
FR2766824B1 (fr) 1997-07-30 1999-09-10 Adir Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101284773A (zh) * 2001-08-09 2008-10-15 小野药品工业株式会社 羧酸衍生物及以它为活性成分的药剂
US20040072802A1 (en) * 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
DE10257785A1 (de) 2002-12-11 2004-07-01 Bayer Healthcare Ag Isophthalsäurederivate

Also Published As

Publication number Publication date
US8318952B2 (en) 2012-11-27
US7763610B2 (en) 2010-07-27
EP1661892A4 (fr) 2009-02-18
IL173898A0 (en) 2006-07-05
JPWO2005021518A1 (ja) 2007-11-01
BRPI0413968A (pt) 2006-10-31
AU2004268865B8 (en) 2011-01-06
MXPA06002152A (es) 2006-05-22
WO2005021518A1 (fr) 2005-03-10
AU2004268865A1 (en) 2005-03-10
CA2537355A1 (fr) 2005-03-10
EP2481732A1 (fr) 2012-08-01
ES2425746T3 (es) 2013-10-17
RU2371436C2 (ru) 2009-10-27
AU2004268865B2 (en) 2010-12-16
KR20060119903A (ko) 2006-11-24
US20060194797A1 (en) 2006-08-31
CA2537355C (fr) 2012-10-09
EP1661892B1 (fr) 2013-07-24
JP4720502B2 (ja) 2011-07-13
RU2006110513A (ru) 2007-10-10
KR101135911B1 (ko) 2012-04-16
EP1661892A1 (fr) 2006-05-31
IL173898A (en) 2012-03-29
US20100234368A1 (en) 2010-09-16
NZ545666A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
BRPI0606870A2 (pt) composto de indol e uso do mesmo
NO20084005L (no) Aminderivater
BR0107934A (pt) Carboxamidas de pirimidina úteis como inibidores de isozimas pde4
NO20083562L (no) Cannabinoidreseptormodulatorer
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20061254L (no) Farmasoytiske blandinger
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
MX2009009443A (es) Compuestos de pirimidina hidrazida como inhibidores de pgds.
NO20063693L (no) Forbindelse og metode for anvendelse
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2010042163A3 (fr) Composés de quinoline en tant qu'inhibiteurs de l'angiogenèse, de la méthionine aminopeptidase humaine et de la sirt1, et méthodes de traitement de troubles
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
CY1108900T1 (el) Πολυθειωμενα γλυκοζιδια και αλατα αυτων
NO20070588L (no) Piperidinderivater som NK1-antagonister.
NO20081014L (no) Sammensetninger
NO20061513L (no) Kondensert ringforbindelse og anvendelse derav
NO20070076L (no) Nye indazolkarboksamider og deres anvendelse
NO20080457L (no) Kjemiske forbindelser
WO2007114848A3 (fr) Composés chimiques
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MX2009013926A (es) Compuestos de etinilindol.
NO20065022L (no) Substituerte 4-alkyl- og 4-alkanoyl-piperidinderivater og deres anvendelse som neurokininantagonister
NO20065757L (no) Purinderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application